{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.000"},{"groupId":"OG001","spread":"0.000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 1; Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.108","value":"116.666"},{"groupId":"OG001","spread":"92.206","value":"84.875"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Cycle 1 Day1; 2 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"625.932","value":"1278.926"},{"groupId":"OG001","spread":"648.225","value":"1070.923"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Cycle 2 Day 1; Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"976.572","value":"1500.143"},{"groupId":"OG001","spread":"858.698","value":"1205.444"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 2 Day 1; 2 hours post dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Blood samples were collected by sparse PK sampling to analyze plasma concentration of major metabolite of Niraparib (M1).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Analysis Set. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)","title":"Phase 2: Plasma Concentrations of Major Metabolite of Niraparib (M1)","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}